Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SNDX

Syndax Pharmaceuticals Inc

May 02 • 04:00PM ET

21.86

Dollar change -0.11
Percentage change -0.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO SCHA VTWO LABU VHT IWN

Index	RUT	P/E	-	EPS (ttm)	-2.96	Insider Own	5.17%	Shs Outstand	84.83M	Perf Week	6.27%
Market Cap	1.86B	Forward P/E	-	EPS next Y	-2.93	Insider Trans	0.00%	Shs Float	80.57M	Perf Month	-8.11%
Income	-209.36M	PEG	-	EPS next Q	-0.98	Inst Own	100.04%	Short Float	11.92%	Perf Quarter	2.92%
Sales	0.00M	P/S	-	EPS this Y	-29.45%	Inst Trans	7.03%	Short Ratio	8.79	Perf Half Y	55.26%
Book/sh	6.53	P/B	3.35	EPS next Y	24.16%	ROA	-37.72%	Short Interest	9.60M	Perf Year	10.46%
Cash/sh	6.72	P/C	3.25	EPS next 5Y	-	ROE	-40.98%	52W Range	11.22 - 25.34	Perf YTD	1.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.41%	ROI	-37.74%	52W High	-13.73%	Beta	1.04
Dividend TTM	-	Quick Ratio	10.00	Sales past 5Y	1801.91%	Gross Margin	-	52W Low	94.92%	ATR (14)	0.89
Dividend Ex-Date	-	Current Ratio	10.00	EPS Y/Y TTM	-20.58%	Oper. Margin	0.00%	RSI (14)	51.22	Volatility	4.62% 3.59%
Employees	184	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.23	Target Price	34.92
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-61.13%	Payout	-	Rel Volume	1.01	Prev Close	21.97
Sales Surprise	-	EPS Surprise	-3.26%	Sales Q/Q	-	Earnings	Feb 27 AMC	Avg Volume	1.09M	Price	21.86
SMA20	1.43%	SMA50	-3.15%	SMA200	14.58%	Trades		Volume	1,102,447	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31
May-25-21	Initiated	Citigroup	Buy	$24
Feb-18-21	Initiated	B. Riley Securities	Buy	$30
Dec-03-20	Initiated	Stifel	Buy	$32
May-22-20	Upgrade	Citigroup	Neutral → Buy	$26 → $23
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25 → $15
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy	$19 → $25

Show Previous Ratings

May-01-24 07:00AM	Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Apr-10-24 04:05PM	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum (PR Newswire)
Apr-08-24 07:00AM	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session (PR Newswire)
Apr-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-28-24 09:54AM	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA (Zacks)
07:00AM	Loading…
07:00AM	Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia (PR Newswire)
06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-26-24 04:05PM	Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia (PR Newswire)
Mar-18-24 07:00AM	Syndax Announces Appointment of Steven Closter as Chief Commercial Officer (PR Newswire) -6.80%
Mar-03-24 08:29AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-28-24 01:10PM	Q4 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:47PM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
Feb-26-24 08:50AM	Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.38%
07:00AM	Loading…
07:00AM	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
Feb-20-24 04:05PM	Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 (PR Newswire)
Feb-02-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-01-24 04:10PM	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
Jan-09-24 01:51PM	Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets. (Barrons.com)
Jan-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-02-24 04:05PM	Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
07:00AM	Syndax Highlights Recent Updates and Anticipated 2024 Milestones (PR Newswire)
Dec-19-23 04:16PM	Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey) -5.30%
Dec-14-23 11:07PM	Syndax Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) +6.65%
04:00PM	Syndax Announces Proposed $150 Million Public Offering of Common Stock (PR Newswire)
Dec-12-23 12:00PM	Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting (PR Newswire)
Dec-11-23 07:30AM	Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials (PR Newswire) +7.75%
Dec-10-23 05:00PM	Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease (Business Wire)
01:34PM	Loading…
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
Dec-04-23 07:00AM	Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting (PR Newswire)
Dec-01-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-21-23 09:00AM	Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting (PR Newswire)
Nov-07-23 07:00AM	Syndax Announces Participation at Stifel Healthcare Conference (PR Newswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
09:56AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 07:29PM	Syndax Pharmaceuticals Inc (SNDX) Reports Q3 2023 Financial Results (GuruFocus.com) +6.18%
04:52PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
09:00AM	Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting (PR Newswire)
09:00AM	Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting (PR Newswire)
Oct-27-23 11:51AM	Bank of America Says Contrarian Buy Signal Could Push Stocks Higher; Here Are 2 Names the Banking Giant Likes Right Now (TipRanks)
Oct-26-23 07:00AM	Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 (PR Newswire) +6.65%
Oct-24-23 07:00AM	Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program (PR Newswire)
Oct-06-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Oct-02-23 07:00AM	Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis (PR Newswire) -7.02%
Sep-29-23 04:05PM	Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 (PR Newswire) -7.10%
Sep-01-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +5.62%
Aug-31-23 04:05PM	Syndax Announces Participation at the Citi 18th Annual BioPharma Conference (PR Newswire)
Aug-04-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Aug-03-23 05:10PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
Jul-25-23 07:00AM	Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 (PR Newswire)
Jul-24-23 07:00AM	Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease (PR Newswire)
Jul-07-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-02-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-24-23 07:00AM	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
May-09-23 09:51AM	Q1 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +6.55%
May-08-23 04:55PM	Syndax: Q1 Earnings Snapshot (AP Finance)
04:05PM	Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
May-01-23 07:00AM	Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 (PR Newswire)
Apr-13-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-07-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-05-23 06:00PM	Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know (Zacks)
Apr-03-23 06:15PM	Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-30-23 07:00AM	Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development (PR Newswire)
Mar-27-23 06:15PM	Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-21-23 06:00PM	Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-15-23 06:00PM	Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know (Zacks)
04:05PM	Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients (PR Newswire)
Mar-14-23 06:15PM	Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know (Zacks)
Mar-06-23 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
01:06AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-28-23 04:03PM	Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
Feb-24-23 09:00AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Feb-21-23 06:00PM	Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know (Zacks)
07:00AM	Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023 (PR Newswire)
Feb-14-23 10:37AM	Syndax (SNDX) to Report Q4 Earnings: What's in the Cards? (Zacks)
07:00AM	Syndax Announces Participation at Upcoming Investor Conferences (PR Newswire)
Feb-13-23 06:00PM	Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Feb-09-23 01:35PM	Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants (Zacks)
Feb-08-23 09:00AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Feb-07-23 06:00PM	Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know (Zacks)
Feb-06-23 08:50AM	Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why (Zacks) -5.11%
Feb-01-23 06:00PM	Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know (Zacks)
Jan-23-23 06:00PM	Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know (Zacks)
07:40AM	Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus (Zacks)
Jan-20-23 08:50AM	Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
07:34AM	Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication (Zacks)
Jan-19-23 10:26AM	Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal (Zacks)
Jan-18-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice (Zacks)
Jan-17-23 06:15PM	Syndax Pharmaceuticals (SNDX) Gains As Market Dips: What You Should Know (Zacks)
09:36AM	Incyte (INCY) Up 7% in a Year: Will the Momentum Continue? (Zacks)
Jan-16-23 09:40AM	Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year? (Zacks)
Jan-11-23 06:15PM	Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know (Zacks)
09:38AM	Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe (Zacks)
Jan-10-23 01:16PM	bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook (Zacks) +8.00%
Jan-06-23 01:50PM	FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA (Zacks)

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morrison Briggs	Director	Aug 09 '23	Option Exercise	8.77	52,855	463,538	70,691	Aug 10 06:50 AM
Morrison Briggs	Director	Aug 09 '23	Sale	18.27	52,855	965,402	17,836	Aug 10 06:50 AM
Meury William	Director	Aug 02 '23	Option Exercise	8.02	83,000	665,250	83,000	Aug 03 09:12 AM
Meury William	Director	Aug 02 '23	Sale	20.46	83,000	1,697,810	48,000	Aug 03 09:12 AM
Morrison Briggs	Director	Jul 10 '23	Option Exercise	8.77	52,855	463,538	70,691	Jul 11 09:23 AM
Morrison Briggs	Director	Jul 10 '23	Sale	20.40	52,855	1,078,068	17,836	Jul 11 09:23 AM
Goldan Keith A.	Chief Financial Officer	Jun 13 '23	Sale	22.31	577	12,873	2,628	Jun 14 04:20 PM
Morrison Briggs	Director	Jun 09 '23	Option Exercise	7.66	52,855	404,787	70,691	Jun 09 05:32 PM
Morrison Briggs	Director	Jun 09 '23	Sale	21.18	52,855	1,119,421	17,836	Jun 09 05:32 PM
Morrison Briggs	Director	May 09 '23	Option Exercise	6.38	52,855	337,215	70,691	May 10 04:11 PM
Morrison Briggs	Director	May 09 '23	Sale	21.41	52,855	1,131,478	17,836	May 10 04:11 PM

Open in Screener

EBS

Emergent Biosolutions Inc

May 02 • 04:00PM ET

3.30

Dollar change +1.37
Percentage change 70.98	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

EBS Emergent Biosolutions Inc daily Stock Chart

Held by: FNDA VTI IWM VXF PRFZ IWN AVUV VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-11.02	Insider Own	4.05%	Shs Outstand	52.20M	Perf Week	69.23%
Market Cap	172.26M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	0.00%	Shs Float	50.09M	Perf Month	46.02%
Income	-565.20M	PEG	-	EPS next Q	-0.94	Inst Own	78.29%	Short Float	11.77%	Perf Quarter	100.00%
Sales	1.19B	P/S	0.15	EPS this Y	80.42%	Inst Trans	-1.89%	Short Ratio	1.92	Perf Half Y	57.89%
Book/sh	12.67	P/B	0.26	EPS next Y	5.74%	ROA	-23.78%	Short Interest	5.89M	Perf Year	-60.10%
Cash/sh	1.51	P/C	2.18	EPS next 5Y	-	ROE	-60.56%	52W Range	1.42 - 10.88	Perf YTD	37.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-50.89%	52W High	-69.67%	Beta	1.19
Dividend TTM	-	Quick Ratio	0.55	Sales past 5Y	10.59%	Gross Margin	36.74%	52W Low	132.39%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	1.08	EPS Y/Y TTM	-231.09%	Oper. Margin	-17.05%	RSI (14)	73.23	Volatility	18.89% 10.72%
Employees	1600	Debt/Eq	1.36	Sales Y/Y TTM	21.14%	Profit Margin	-47.68%	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.67	EPS Q/Q	104.73%	Payout	-	Rel Volume	49.34	Prev Close	1.93
Sales Surprise	36.39%	EPS Surprise	160.20%	Sales Q/Q	81.95%	Earnings	May 01 AMC	Avg Volume	3.06M	Price	3.30
SMA20	58.65%	SMA50	34.77%	SMA200	8.09%	Trades		Volume	151,130,795	Change	70.98%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy	$5
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy	$22
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$23 → $9
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy	$77
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy	$150
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$112
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$112
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$110
Sep-14-20	Resumed	JP Morgan	Neutral	$103
Jul-31-20	Reiterated	Chardan Capital Markets	Buy	$86 → $112
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy	$53 → $57

Show Previous Ratings

Today 01:48PM	Top Midday Gainers (MT Newswires) +70.98%
12:33PM	Q1 2024 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents)
12:10PM	MercadoLibre Stock Split: Will MELI Investors See Wishes Come True Today? (InvestorPlace)
11:27AM	JPMorgan Just Raised Its Price Target on Carvana (CVNA) Stock (InvestorPlace)
11:13AM	Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts (InvestorPlace)
10:38AM	Loading…
10:38AM	Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	Top Premarket Gainers (MT Newswires)
07:58AM	Why Is Emergent BioSolutions (EBS) Stock Up 57% Today? (InvestorPlace)
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
03:54AM	Emergent BioSolutions Inc (EBS) (Q1 2024) Earnings Call Transcript Highlights: A Strong Start ... (GuruFocus.com)
12:42AM	PRESS DIGEST- Wall Street Journal - May 2 (Reuters)
May-01-24 11:45PM	Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript (Motley Fool)
10:56PM	EBS Stock Earnings: Emergent BioSolutions Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:15PM	Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ... (GuruFocus.com)
05:53PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press Finance)
05:52PM	Loading…
05:52PM	Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities (The Wall Street Journal)
04:57PM	Emergent BioSolutions Reports First Quarter 2024 Financial Results (GlobeNewswire)
04:34PM	UPDATE 2-Emergent BioSolutions to lay off about 300 employees (Reuters)
04:21PM	Emergent BioSolutions to cut 300 jobs (Reuters)
04:10PM	Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position (GlobeNewswire)
11:03AM	Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone (GlobeNewswire)
Apr-30-24 05:26PM	Emergent BioSolutions Announces Amendment to its Existing Credit Facility (GlobeNewswire)
Apr-22-24 08:05AM	Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 (GlobeNewswire) +5.88%
Apr-01-24 08:00AM	Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive (GlobeNewswire) -9.09%
Mar-28-24 08:15AM	Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis (GlobeNewswire)
Mar-25-24 08:05AM	Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility (GlobeNewswire) +5.39%
Mar-07-24 01:58PM	Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) -15.03%
12:34PM	Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales (Zacks)
10:33AM	Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:35AM	Q4 2023 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents)
11:30PM	Loading…
Mar-06-24 11:30PM	Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript (Motley Fool)
09:53PM	EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:55PM	Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:20PM	Emergent Biosolutions: Q4 Earnings Snapshot (Associated Press Finance)
04:31PM	Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results (GlobeNewswire)
Feb-29-24 07:00AM	Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 (GlobeNewswire)
Feb-21-24 03:24PM	Why Is Emergent BioSolutions (EBS) Stock Up 70% Today? (InvestorPlace) +78.29%
07:35AM	UPDATE 2-Emergent appoints former Bausch + Lomb CEO to head company (Reuters)
07:06AM	Emergent names Joseph Papa as new CEO (Reuters)
07:00AM	Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO (GlobeNewswire)
Jan-17-24 11:55AM	Emergent extends shelf life of opioid overdose reversal drug Narcan (Reuters) -5.42%
Jan-12-24 02:20PM	Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine (Zacks)
Jan-11-24 08:00AM	Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (GlobeNewswire)
Jan-09-24 07:30AM	Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 (GlobeNewswire)
Dec-12-23 06:53AM	EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023 (InvestorPlace)
Dec-11-23 10:05AM	Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -14.86%
09:03AM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
Nov-29-23 11:56AM	Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine (Zacks) +6.97%
Nov-28-23 06:59AM	Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (GlobeNewswire)
Nov-24-23 07:30AM	Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing (GlobeNewswire)
Nov-09-23 01:19PM	Emergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 11:00PM	Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript (Motley Fool) -6.36%
05:38PM	Emergent BioSolutions Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 04:45PM	UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023 (GlobeNewswire)
Oct-19-23 06:30AM	Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic (PR Newswire)
Oct-02-23 07:00AM	Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors (GlobeNewswire) -7.06%
Sep-07-23 11:30AM	Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report? (Zacks)
Aug-30-23 05:59AM	Emergent BioSolutions NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency (GlobeNewswire) +11.55%
Aug-29-23 09:37AM	Oracle upgraded, Farfetch downgraded: Wall Street's top analyst calls (The Fly) -7.92%
Aug-25-23 11:36AM	Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why (Zacks)
Aug-23-23 12:33PM	Moody's downgrades Emergent BioSolutions' credit rating, citing unpredictable revenue outlook (American City Business Journals)
Aug-22-23 11:42AM	Why Emergent BioSolutions Stock Is Tumbling Today (Motley Fool) -5.88%
Aug-21-23 06:00PM	Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600 (PR Newswire)
Aug-17-23 09:57AM	Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study (Zacks)
09:35AM	Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS) (Zacks)
Aug-16-23 09:35AM	Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS) (Zacks)
Aug-09-23 09:26AM	Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat (Zacks) -17.78%
08:29AM	Q2 2023 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents)
12:30AM	Emergent BioSolutions (EBS) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-08-23 07:40PM	Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:29PM	Emergent Biosolutions: Q2 Earnings Snapshot (AP Finance)
04:31PM	Emergent BioSolutions Reports Financial Results for Second Quarter 2023 (GlobeNewswire)
08:23AM	Emergent BioSolutions to lay off 400 as its scales back its contract manufacturing business (American City Business Journals)
07:50AM	Emergent BioSolutions to lay off about 400 employees (Reuters)
07:44AM	UPDATE 1-Emergent BioSolutions to lay off about 400 employees (Reuters)
07:15AM	Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position (GlobeNewswire)
Aug-07-23 11:32AM	Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More (Zacks)
Aug-04-23 09:21AM	4 Biotech Stocks Set to Outpace Q2 Earnings Estimates (Zacks)
Aug-01-23 12:06PM	Gaithersburg's Emergent BioSolutions lands large federal contract to boost development of Ebola drug (American City Business Journals) +14.97%
Jul-31-23 04:05PM	Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga Treatment for Ebola (GlobeNewswire)
Jul-25-23 06:30AM	Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023 (GlobeNewswire)
Jul-20-23 06:31PM	UPDATE 1-US FDA approves Emergent BioSolutions' anthrax vaccine (Reuters)
06:15PM	US FDA approves Emergent BioSolutions' anthrax vaccine (Reuters)
06:03PM	Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use (GlobeNewswire)
Jun-27-23 05:30PM	Why Emergent BioSolutions Stock Dived by 9% Today (Motley Fool) -8.95%
08:02AM	Emergent BioSolutions CEO Robert Kramer to retire immediately (Reuters)
07:55AM	Emergent BioSolutions Announces CEO Transition (GlobeNewswire)
Jun-26-23 05:30AM	Better Recovery-Story Buy: Emergent BioSolutions or Invitae? (Motley Fool)
Jun-21-23 08:00PM	EBS: Raising target price to $8.00 (Argus Research)
11:30AM	Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-09-23 08:20AM	Is Emergent BioSolutions Stock a Buy Now? (Motley Fool)
Jun-08-23 11:30AM	Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report? (Zacks)
Jun-07-23 08:20AM	Down 75%, Can Emergent BioSolutions Turn Things Around? (Motley Fool) +6.12%
Jun-05-23 09:39AM	Shareholders in Emergent BioSolutions (NYSE:EBS) are in the red if they invested three years ago (Simply Wall St.)
May-17-23 06:21AM	New Strong Sell Stocks for May 17th (Zacks)
May-15-23 06:27PM	Why Emergent BioSolutions Stock Inched Slightly Higher Today (Motley Fool)
07:58AM	Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic (GlobeNewswire)
May-11-23 06:30AM	Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT (GlobeNewswire)
May-10-23 10:47AM	Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat (Zacks) +11.44%

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zoon Kathryn C	Director	Jun 02 '23	Sale	8.35	1,830	15,280	49,971	Jul 24 08:28 AM
Zoon Kathryn C	Director	May 25 '23	Sale	8.38	1,700	14,246	51,801	Jul 24 08:28 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SNDX

Syndax Pharmaceuticals Inc

EBS

Emergent Biosolutions Inc

Upgrade your FINVIZ experience